In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Strategy Market Intelligence

Snapshot: November Highlights

  • Data

Executive Summary

A selection of articles you might have missed from November 2022, during which In Vivo shone the spotlight on the Asia Pacific region.

You may also be interested in...



Seeing The Wood From The Shrubs: Azalea Begins Tests Of Its Smart Contact Lens

The Belgian start-up is developing a scleral contact lens with an inbuilt LCD screen capable of filtering light – offering a non-surgical solution to a variety of ophthalmic conditions.

Octave Biosciences Takes It Up Another Semitone With Michael J Fox Foundation Grant

The diagnostics company has secured $10m from the foundation to develop a biomarker test for Parkinson’s disease.

No, I Am Spartacus – Embecta Joins The Quell Against GLP-1 Hype

Embecta, which recently completed its spin-off from Becton Dickinson, is forging ahead with its insulin injector-based business strategy, GLP-1s be damned. 

Table

View full table

Topics

Tags:
BioPharmaceutical Strategy Market Intelligence
Latest Headlines

Industry Leaderboard Gains And Dips Were Still Marked By COVID-19

The New Antibodies Revolutionizing Medicine

Macro Challenges Make Calls On Newly Resilient Medtechs

Will Medicare Price Negotiation Stop Post-Approval R&D?

See All
UsernamePublicRestriction

Register

IV146787

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By